Reneo Pharmaceuticals prices public offering of 6.875M shares at $8.00, expects net proceeds ~$58.2M

OnKure Therapeutics, Inc.

Public offering of 6.875M shares at $8.00/share; underwriters exercised overallotment for 1.031M additional shares in full.
Net proceeds expected approx. $58.2M after underwriting discounts and expenses.
Concurrent $5.0M private placement to Abingworth Bioventures at same $8.00/share, closing conditioned on public offering.
Offering expected to close May 8, 2023; shares sold under effective S-3 shelf registration.
Jefferies, BofA Securities, and Piper Sandler act as joint book-running managers.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

OnKure Therapeutics, Inc. entered into Underwriting Agreement with Jefferies LLC, BofA Securities, Inc. and Piper Sandler & Co., as representatives of the several underwriters valued at 6,875,000 shares of common stock at $8.00 per share; additional 1,031,250 shares option exercised; n (effective 2023-05-03).

Action: entry
Agreement: underwriting
Counterparty: Jefferies LLC, BofA Securities, Inc. and Piper Sandler & Co., as representatives of the several underwriters
Value: 6,875,000 shares of common stock at $8.00 per share; additional 1,031,250 shares option exercised; n
Effective: 2023-05-03

Exact text from the filing

On May 3, 2023, Reneo Pharmaceuticals, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Jefferies LLC, BofA Securities, Inc. and Piper Sandler & Co., as representatives of the several underwriters listed on Schedule A thereto (collectively, the “Underwriters”), relating to an offering (the “Public Offering”) of 6,875,000 shares (the “Shares”) of the Company’s common stock, $0.0001 par value per share (“Common Stock”).

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

OnKure Therapeutics, Inc. entered into Securities Purchase Agreement with Abingworth Bioventures 8 LP valued at 625,000 shares of common stock at $8.00 per share; total purchase price approx. $5.0 million (effective 2023-05-02).

Action: entry
Agreement: equity purchase
Counterparty: Abingworth Bioventures 8 LP
Value: 625,000 shares of common stock at $8.00 per share; total purchase price approx. $5.0 million
Effective: 2023-05-02

Exact text from the filing

On May 2, 2023, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with Abingworth Bioventures 8 LP. (“Abingworth”).

View on SEC.gov

85 material agreements filed in the last 30 days. Browse all material agreements →

OnKure Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-137165

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.